Berkeley’s future
This article was originally published in The Tan Sheet
Executive Summary
Berkeley Premium Nutraceuticals "is working through [its] current difficulties and seeing positive results," but officials say a company name change may be needed as the Enzyte "male enhancement" supplement marketer "tries to make a clean break from the past," according to a May 27 release. Four executives of the firm were convicted in February on charges of fraud and money laundering (1"The Tan Sheet" March 3, 2008, In Brief). Still, the Cincinnati-base company maintains that "with innovative marketing, customer loyalty and demand ... Berkeley will get back to the $200 million per-year company it used to be." Despite the recent economic downturn, Berkeley says it hired 70 employees in the previous 45 days and looks to double the size of its call center by the end of 2008...
You may also be interested in...
“Smiling Bob” firm convicted
A federal jury on Feb. 22 convicts four executives of Cincinnati-based Berkeley Premium Nutraceuticals, marketer of Enzyte "male enhancement" supplements, of conspiracy and fraud on criminal charges of money laundering, fraud and obstruction of justice. A federal grand jury indicted the firm, Berkeley's President Steve Warshak, his mother and five additional defendants and co-conspirators on a total of 112 criminal charges in September 2006 (1"The Tan Sheet" Sept. 25, 2006, In Brief). The trial jury in the U.S. District Court for Southern Ohio also found on Feb. 26 that Berkeley, Warshak, his mother and TCI Media, another company owned by Warshak, should forfeit to the U.S. more than $33 million in assets that were proceeds of the crimes. In addition, the jury convicted Paul J. Kellogg and Steven P. Pugh. Berkeley also settled with six states in March 2006 for $2.5 million (2"The Tan Sheet" March 6, 2006, p. 8)...
European SEAC Opinion Unchanged: Microplastics Must Be Out Of All Cosmetics Within Six Years
The final opinion of ECHA’s Socio-Economic Analysis Committee, published on 1 March, is largely unchanged from its July 2020 draft opinion with regard to microplastic in cosmetic products. That means industry may have to convince EU member state authorities that the restriction proposal has a serious proportionality problem.
QUOTED. 2 March 2021. Michael Coyle.
Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: